Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China
Purpose Lentinan is a polysaccharide extracted from Shiitake mushrooms that have been used to improve general health for thousands of years in Asia. Lentinan injection is a clinically approved drug in several countries in Asia. The purpose of this study is to review the structure, preclinical and cl...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2018-11, Vol.144 (11), p.2177-2186 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2186 |
|---|---|
| container_issue | 11 |
| container_start_page | 2177 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 144 |
| creator | Zhang, Yiran Zhang, Meng Jiang, Yifei Li, Xiulian He, Yanli Zeng, Pengjiao Guo, Zhihua Chang, Yajing Luo, Heng Liu, Yong Hao, Cui Wang, Hua Zhang, Guoqing Zhang, Lijuan |
| description | Purpose
Lentinan is a polysaccharide extracted from
Shiitake
mushrooms that have been used to improve general health for thousands of years in Asia. Lentinan injection is a clinically approved drug in several countries in Asia. The purpose of this study is to review the structure, preclinical and clinical studies, and molecular mechanisms of lentinan. Most importantly, the clinical effectiveness of lentinan as an adjuvant therapeutic drug in treating patients with lung cancer in China during the past 12 years is analyzed statistically.
Methods
We carried out literature search of randomized controlled trials (RCTs) published from 2004 to 2016 based on CNKI (China National Knowledge Infrastructure), VIP (Chongqing VIP Chinese Scientific Journals Database) and Wanfang database, and 38 eligible RCTs of lentinan-associated lung cancer treatment were identified, containing 3,117 patients.
Results
The structure and function relationship and underlying molecular mechanism of lentinan as an immunostimulant has been summarized. The mean value of overall response rate in treating lung cancer was increased from 43.3% of chemotherapy alone to 56.9% of lentinan plus chemotherapy [
p
|
| doi_str_mv | 10.1007/s00432-018-2718-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2076242117</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2075200880</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3531-22b9463aa4f803175afd889f2ae4a7add7d21c12d6ec837c35c37dd3eb441eb73</originalsourceid><addsrcrecordid>eNp1kc9O3DAQxq2qqCxLH6AXZKmXXgIeO1mH3qpV-SOtxAXO1qw9Aa8SZ2snRfs2PEufDIeFVqrEZSyPf983I3-MfQFxCkLosyREqWQhoC6kzgU-sBlMHVCq-shmAjQUlYTFITtKaSPyvdLyEztUL0KtZ2yzojD4gIFj4rn6rhtDPzxQxC2Ng7e86SMfImGm7nk75mIxWIrfOfJIvz098r7hIP887Qhj4rb1wVtseRpG5ylxH_jyIY84ZgcNtok-v55zdnfx83Z5VaxuLq-XP1aFVZWCQsr1eblQiGVTC5U3xsbV9XkjkUrU6Jx2EixItyBbK51FVmnnFK3LEmit1Zx92_tuY_9rpDSYzidLbYuB-jEZKfRClhJgQr_-h276MYa83URVUog67zBnsKds7FOK1Jht9B3GnQFhpiDMPgiTgzBTEAay5uTVeVx35P4q3n4-A3IPpPwU7in-G_2-6zPL35NN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2075200880</pqid></control><display><type>article</type><title>Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China</title><source>SpringerNature Journals</source><creator>Zhang, Yiran ; Zhang, Meng ; Jiang, Yifei ; Li, Xiulian ; He, Yanli ; Zeng, Pengjiao ; Guo, Zhihua ; Chang, Yajing ; Luo, Heng ; Liu, Yong ; Hao, Cui ; Wang, Hua ; Zhang, Guoqing ; Zhang, Lijuan</creator><creatorcontrib>Zhang, Yiran ; Zhang, Meng ; Jiang, Yifei ; Li, Xiulian ; He, Yanli ; Zeng, Pengjiao ; Guo, Zhihua ; Chang, Yajing ; Luo, Heng ; Liu, Yong ; Hao, Cui ; Wang, Hua ; Zhang, Guoqing ; Zhang, Lijuan</creatorcontrib><description>Purpose
Lentinan is a polysaccharide extracted from
Shiitake
mushrooms that have been used to improve general health for thousands of years in Asia. Lentinan injection is a clinically approved drug in several countries in Asia. The purpose of this study is to review the structure, preclinical and clinical studies, and molecular mechanisms of lentinan. Most importantly, the clinical effectiveness of lentinan as an adjuvant therapeutic drug in treating patients with lung cancer in China during the past 12 years is analyzed statistically.
Methods
We carried out literature search of randomized controlled trials (RCTs) published from 2004 to 2016 based on CNKI (China National Knowledge Infrastructure), VIP (Chongqing VIP Chinese Scientific Journals Database) and Wanfang database, and 38 eligible RCTs of lentinan-associated lung cancer treatment were identified, containing 3,117 patients.
Results
The structure and function relationship and underlying molecular mechanism of lentinan as an immunostimulant has been summarized. The mean value of overall response rate in treating lung cancer was increased from 43.3% of chemotherapy alone to 56.9% of lentinan plus chemotherapy [
p
< 0.001, 95% confidence interval (CI) 0.102–0.170]. Compared with chemotherapy alone, lentinan plus chemotherapy showed more efficacy in treating lung cancer (pooled RR 0.79, 95% CI 0.74–0.85) and no statistical heterogeneity was found among studies (
I
2
= 11%).
Conclusion
Clinical data presented in the past 12 years shows that lentinan is effective not only in improving quality of life, but also in promoting the efficacy of chemotherapy during lung cancer treatment.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-018-2718-1</identifier><identifier>PMID: 30043277</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer Research ; Cancer therapies ; Chemotherapy ; Clinical trials ; Hematology ; Immunostimulants ; Internal Medicine ; Lentinan ; Lung cancer ; Medicine ; Medicine & Public Health ; Molecular modelling ; Oncology ; Patients ; Polysaccharides ; Quality of life ; Review – Clinical Oncology ; Structure-function relationships ; Vasoactive intestinal peptide</subject><ispartof>Journal of cancer research and clinical oncology, 2018-11, Vol.144 (11), p.2177-2186</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>Journal of Cancer Research and Clinical Oncology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3531-22b9463aa4f803175afd889f2ae4a7add7d21c12d6ec837c35c37dd3eb441eb73</citedby><cites>FETCH-LOGICAL-c3531-22b9463aa4f803175afd889f2ae4a7add7d21c12d6ec837c35c37dd3eb441eb73</cites><orcidid>0000-0002-4357-6566</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-018-2718-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-018-2718-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30043277$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yiran</creatorcontrib><creatorcontrib>Zhang, Meng</creatorcontrib><creatorcontrib>Jiang, Yifei</creatorcontrib><creatorcontrib>Li, Xiulian</creatorcontrib><creatorcontrib>He, Yanli</creatorcontrib><creatorcontrib>Zeng, Pengjiao</creatorcontrib><creatorcontrib>Guo, Zhihua</creatorcontrib><creatorcontrib>Chang, Yajing</creatorcontrib><creatorcontrib>Luo, Heng</creatorcontrib><creatorcontrib>Liu, Yong</creatorcontrib><creatorcontrib>Hao, Cui</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Zhang, Guoqing</creatorcontrib><creatorcontrib>Zhang, Lijuan</creatorcontrib><title>Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
Lentinan is a polysaccharide extracted from
Shiitake
mushrooms that have been used to improve general health for thousands of years in Asia. Lentinan injection is a clinically approved drug in several countries in Asia. The purpose of this study is to review the structure, preclinical and clinical studies, and molecular mechanisms of lentinan. Most importantly, the clinical effectiveness of lentinan as an adjuvant therapeutic drug in treating patients with lung cancer in China during the past 12 years is analyzed statistically.
Methods
We carried out literature search of randomized controlled trials (RCTs) published from 2004 to 2016 based on CNKI (China National Knowledge Infrastructure), VIP (Chongqing VIP Chinese Scientific Journals Database) and Wanfang database, and 38 eligible RCTs of lentinan-associated lung cancer treatment were identified, containing 3,117 patients.
Results
The structure and function relationship and underlying molecular mechanism of lentinan as an immunostimulant has been summarized. The mean value of overall response rate in treating lung cancer was increased from 43.3% of chemotherapy alone to 56.9% of lentinan plus chemotherapy [
p
< 0.001, 95% confidence interval (CI) 0.102–0.170]. Compared with chemotherapy alone, lentinan plus chemotherapy showed more efficacy in treating lung cancer (pooled RR 0.79, 95% CI 0.74–0.85) and no statistical heterogeneity was found among studies (
I
2
= 11%).
Conclusion
Clinical data presented in the past 12 years shows that lentinan is effective not only in improving quality of life, but also in promoting the efficacy of chemotherapy during lung cancer treatment.</description><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Hematology</subject><subject>Immunostimulants</subject><subject>Internal Medicine</subject><subject>Lentinan</subject><subject>Lung cancer</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Molecular modelling</subject><subject>Oncology</subject><subject>Patients</subject><subject>Polysaccharides</subject><subject>Quality of life</subject><subject>Review – Clinical Oncology</subject><subject>Structure-function relationships</subject><subject>Vasoactive intestinal peptide</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kc9O3DAQxq2qqCxLH6AXZKmXXgIeO1mH3qpV-SOtxAXO1qw9Aa8SZ2snRfs2PEufDIeFVqrEZSyPf983I3-MfQFxCkLosyREqWQhoC6kzgU-sBlMHVCq-shmAjQUlYTFITtKaSPyvdLyEztUL0KtZ2yzojD4gIFj4rn6rhtDPzxQxC2Ng7e86SMfImGm7nk75mIxWIrfOfJIvz098r7hIP887Qhj4rb1wVtseRpG5ylxH_jyIY84ZgcNtok-v55zdnfx83Z5VaxuLq-XP1aFVZWCQsr1eblQiGVTC5U3xsbV9XkjkUrU6Jx2EixItyBbK51FVmnnFK3LEmit1Zx92_tuY_9rpDSYzidLbYuB-jEZKfRClhJgQr_-h276MYa83URVUog67zBnsKds7FOK1Jht9B3GnQFhpiDMPgiTgzBTEAay5uTVeVx35P4q3n4-A3IPpPwU7in-G_2-6zPL35NN</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Zhang, Yiran</creator><creator>Zhang, Meng</creator><creator>Jiang, Yifei</creator><creator>Li, Xiulian</creator><creator>He, Yanli</creator><creator>Zeng, Pengjiao</creator><creator>Guo, Zhihua</creator><creator>Chang, Yajing</creator><creator>Luo, Heng</creator><creator>Liu, Yong</creator><creator>Hao, Cui</creator><creator>Wang, Hua</creator><creator>Zhang, Guoqing</creator><creator>Zhang, Lijuan</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4357-6566</orcidid></search><sort><creationdate>20181101</creationdate><title>Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China</title><author>Zhang, Yiran ; Zhang, Meng ; Jiang, Yifei ; Li, Xiulian ; He, Yanli ; Zeng, Pengjiao ; Guo, Zhihua ; Chang, Yajing ; Luo, Heng ; Liu, Yong ; Hao, Cui ; Wang, Hua ; Zhang, Guoqing ; Zhang, Lijuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3531-22b9463aa4f803175afd889f2ae4a7add7d21c12d6ec837c35c37dd3eb441eb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Hematology</topic><topic>Immunostimulants</topic><topic>Internal Medicine</topic><topic>Lentinan</topic><topic>Lung cancer</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Molecular modelling</topic><topic>Oncology</topic><topic>Patients</topic><topic>Polysaccharides</topic><topic>Quality of life</topic><topic>Review – Clinical Oncology</topic><topic>Structure-function relationships</topic><topic>Vasoactive intestinal peptide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yiran</creatorcontrib><creatorcontrib>Zhang, Meng</creatorcontrib><creatorcontrib>Jiang, Yifei</creatorcontrib><creatorcontrib>Li, Xiulian</creatorcontrib><creatorcontrib>He, Yanli</creatorcontrib><creatorcontrib>Zeng, Pengjiao</creatorcontrib><creatorcontrib>Guo, Zhihua</creatorcontrib><creatorcontrib>Chang, Yajing</creatorcontrib><creatorcontrib>Luo, Heng</creatorcontrib><creatorcontrib>Liu, Yong</creatorcontrib><creatorcontrib>Hao, Cui</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Zhang, Guoqing</creatorcontrib><creatorcontrib>Zhang, Lijuan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yiran</au><au>Zhang, Meng</au><au>Jiang, Yifei</au><au>Li, Xiulian</au><au>He, Yanli</au><au>Zeng, Pengjiao</au><au>Guo, Zhihua</au><au>Chang, Yajing</au><au>Luo, Heng</au><au>Liu, Yong</au><au>Hao, Cui</au><au>Wang, Hua</au><au>Zhang, Guoqing</au><au>Zhang, Lijuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>144</volume><issue>11</issue><spage>2177</spage><epage>2186</epage><pages>2177-2186</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
Lentinan is a polysaccharide extracted from
Shiitake
mushrooms that have been used to improve general health for thousands of years in Asia. Lentinan injection is a clinically approved drug in several countries in Asia. The purpose of this study is to review the structure, preclinical and clinical studies, and molecular mechanisms of lentinan. Most importantly, the clinical effectiveness of lentinan as an adjuvant therapeutic drug in treating patients with lung cancer in China during the past 12 years is analyzed statistically.
Methods
We carried out literature search of randomized controlled trials (RCTs) published from 2004 to 2016 based on CNKI (China National Knowledge Infrastructure), VIP (Chongqing VIP Chinese Scientific Journals Database) and Wanfang database, and 38 eligible RCTs of lentinan-associated lung cancer treatment were identified, containing 3,117 patients.
Results
The structure and function relationship and underlying molecular mechanism of lentinan as an immunostimulant has been summarized. The mean value of overall response rate in treating lung cancer was increased from 43.3% of chemotherapy alone to 56.9% of lentinan plus chemotherapy [
p
< 0.001, 95% confidence interval (CI) 0.102–0.170]. Compared with chemotherapy alone, lentinan plus chemotherapy showed more efficacy in treating lung cancer (pooled RR 0.79, 95% CI 0.74–0.85) and no statistical heterogeneity was found among studies (
I
2
= 11%).
Conclusion
Clinical data presented in the past 12 years shows that lentinan is effective not only in improving quality of life, but also in promoting the efficacy of chemotherapy during lung cancer treatment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30043277</pmid><doi>10.1007/s00432-018-2718-1</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4357-6566</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2018-11, Vol.144 (11), p.2177-2186 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2076242117 |
| source | SpringerNature Journals |
| subjects | Cancer Research Cancer therapies Chemotherapy Clinical trials Hematology Immunostimulants Internal Medicine Lentinan Lung cancer Medicine Medicine & Public Health Molecular modelling Oncology Patients Polysaccharides Quality of life Review – Clinical Oncology Structure-function relationships Vasoactive intestinal peptide |
| title | Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T02%3A20%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lentinan%20as%20an%20immunotherapeutic%20for%20treating%20lung%20cancer:%20a%20review%20of%2012%C2%A0years%20clinical%20studies%20in%20China&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Zhang,%20Yiran&rft.date=2018-11-01&rft.volume=144&rft.issue=11&rft.spage=2177&rft.epage=2186&rft.pages=2177-2186&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-018-2718-1&rft_dat=%3Cproquest_cross%3E2075200880%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2075200880&rft_id=info:pmid/30043277&rfr_iscdi=true |